Weekly Report: what happened at AMPH last week (0708-0712)?
Weekly Report · 11h ago
U.S. Senate passes bill to trim Big Pharma "patent thickets"
U.S. Senate passes bill to trim Big Pharma "patent thickets" to hinder generic competition. The bill is intended to ease the entrance of biosimilars and other generic drugs onto the market. The Affordable Prescriptions for Patients Act moves next to the U.s. House for consideration.
Seeking Alpha · 3d ago
Bank of America Securities Reaffirms Their Hold Rating on Amphastar Pharmaceuticals (AMPH)
TipRanks · 5d ago
Weekly Report: what happened at AMPH last week (0701-0705)?
Weekly Report · 07/08 09:08
Do Amphastar Pharmaceuticals' (NASDAQ:AMPH) Earnings Warrant Your Attention?
Amphastar Pharmaceuticals (NASDAQ:AMPH) has grown its earnings per share by 65% over the last year. The company has a strong track record of growing its revenue and profit. Amphastar pharmaceuticals has a large amount of wealth invested in the company. The growth and insider confidence of the company is a good sign for investors. It is one of several companies in the US with promising growth potential.
Simply Wall St · 07/05 10:32
Amphastar Pharmaceuticals Enters Oversold Territory (AMPH)
NASDAQ · 07/02 16:27
Amphastar Pharmaceuticals: Shining Star Soon To Fade With Competitive Pressures Looming
Amphastar Pharmaceuticals (AMPH) has been up 100% over the last three years. Black Mamba believes Amphastar's growth has been buoyed by temporary factors. The company has benefited from a tornado that hit a Pfizer facility. Three new competitors are about to launch glucagon, and Primatene's patent expires in 2026. The Company's epinephrine revenues are likely to disappoint investors. Black mamba sees 50%+ downside risk in the share price.
Seeking Alpha · 07/01 13:00
Weekly Report: what happened at AMPH last week (0624-0628)?
Weekly Report · 07/01 09:08
Amphastar Pharmaceuticals Price Target Maintained With a $71.00/Share by Piper Sandler
Dow Jones · 06/27 16:10
Piper Sandler Reiterates Overweight on Amphastar Pharma, Maintains $71 Price Target
Benzinga · 06/27 15:59
Analysts Offer Insights on Healthcare Companies: Amphastar Pharmaceuticals (AMPH), Verona Pharma (VRNA) and Henry Schein (HSIC)
TipRanks · 06/27 10:33
Piper Sandler Keeps Their Buy Rating on Amphastar Pharmaceuticals (AMPH)
TipRanks · 06/27 10:32
Weekly Report: what happened at AMPH last week (0617-0621)?
Weekly Report · 06/24 09:09
Those who invested in Amphastar Pharmaceuticals (NASDAQ:AMPH) three years ago are up 101%
Amphastar Pharmaceuticals, Inc. Share price has risen 101% in the last three years. The company has grown its earnings per share at 291% per year over three years, but the share price hasn't kept pace. Amphastar pharmaceuticals shareholders are down 26% for the year. Long term shareholders have made a gain of 15% a year over half a decade. The share price of the company has softened 2.8% over the last week.
Simply Wall St · 06/17 14:33
Weekly Report: what happened at AMPH last week (0610-0614)?
Weekly Report · 06/17 09:08
Weekly Report: what happened at AMPH last week (0603-0607)?
Weekly Report · 06/10 09:08
Amphastar Pharmaceuticals Advances Governance and Shareholder Value
TipRanks · 06/04 21:02
Amphastar adds $50M to share buyback program
Amphastar Pharmaceuticals adds $50M to share buyback program. Generic drug developer has lost more than 30% of its value this year. Amphastar says the move will counter the effect of share dilution created by employee compensation. The company's board of directors greenlighted the increase on Monday.
Seeking Alpha · 06/04 13:29
Reuters · 06/04 10:17
Weekly Report: what happened at AMPH last week (0527-0531)?
Weekly Report · 06/03 09:09
Webull provides a variety of real-time AMPH stock news. You can receive the latest news about Amphastar Pharma through multiple platforms. This information may help you make smarter investment decisions.
About AMPH
Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically challenging generic and injectable, inhalation, and intranasal products. Additionally, it sells insulin API products. Most of its finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. Its segments include finished pharmaceutical products and API products. The finished pharmaceutical products segment manufactures, markets and distributes Primatene MIST, epinephrine, glucagon, phytonadione, lidocaine, enoxaparin, naloxone, as well as various other critical and non-critical care drugs. The API segment manufactures and distributes RHI API and porcine insulin API for external customers and internal product development. Its pipeline has over 20 product candidates, including generic ANDAs, biosimilar, and others.